RBR-4f9cdj进行中（未招募）4 期
Clinical trial to evaluate efficacy, safety and time of remission of Oral Isotretinoin in low dose compared to Doxycycline Hydrochloride in the treatment of papule pustular Rosacea
niversidade Federal De São Paulo - UNIFESP0 个研究点开始时间: 2020年5月21日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 20Y 至 75Y（—）
入选标准
- •Signature of the Free and Informed Consent Form (ICF) and Authorization Form for Photography before any study procedure; men or women aged between 20 and 75 years old, in good health; clinical diagnosis of papular pustular rosacea, with or without ocular involvement, with or without the presence of phyma, and who have been in the active phase of the disease for at least 1 month before the date of inclusion; participants must present on the day of inclusion at least 6 active lesions on the face (papules or pustules), that is, a score greater than or equal to 3 of the static score of 8 points for global assessment of rosacea by the investigator (Investigator's Global Assessment of Rosacea: 8 Point Static Score); absence of topical or systemic treatment, except sunscreens, for at least 3 months; absence of antibiotic therapy (cyclins, macrolides, metronidazole, azalides), for any reason, for at least 3 months; absence of previous treatment with oral isotretinoin or other systemic retinoid; absence of chemotherapy in the last 3 months; absence of a history of hypersensitivity to the study drugs; absence of infectious or other inflammatory dermatoses on the face; absence of clinical evidence or personal history of immunosuppression; absence of habit of drinking alcoholic beverages; absence of photodermatosis; absence of a previous or current history of collagen diseases; agreement to avoid sun exposure throughout the study and agreement with the conditions of the study, ability to understand and strictly follow the guidelines received and availability to attend periodic reevaluations.
排除标准
- •Men and women who do not agree with the conditions of the study or without the ability to understand and strictly follow the guidelines received, without availability to attend periodic reevaluations or who refuse to sign the ICF; pregnant or lactating women; women of childbearing age and with sexual activity who refuse to use any method of contraception, such as oral, implantable, injectable or intrauterine contraceptives, introduced at least 120 days after the start of treatment; participant with exclusively phymatous rosacea (type 4); report of abuse of alcoholic beverages and / or illicit drugs; topical or systemic treatment, except sunscreens, for less than 3 months; use of antibiotic therapy (cyclins, macrolides, metronidazole, azalides), for any reason, for at least 3 months; previous treatment with oral isotretinoin; history of non-adherence to previous clinical treatments; previous or current history of collagen diseases; clinical evidence or history of immunodeficiency; use of any immunosuppressive and, or immunomodulatory medication in the last 3 months, topical or systemic; chemotherapy in the last 3 months; history of inflammatory bowel disease or regional enteritis and / or similar symptoms and any clinical observation made by the investigator that prevents participation in the study; presence of significant hepatic laboratory alterations, that is, values of transaminases 2 times above the upper limit of normality; diabetic patients, with fasting blood glucose values above 110mg / dl; presence of significant lipid changes (triglycerides above 300 mg / dl; total cholesterol above 250 mg / dl); presence of leukopenia (leukocytes under 3000 / mm3); history of hypersensitivity to isotretinoin and parabens or doxycycline hydrochloride; previous history of hypervitaminosis A; previous history of bone and or muscle changes and patients in use or who may need the following medications, for systemic use, due to the risk of interaction with the study drug: vitamin A or vitamin complexes with vitamin A up to 30 days ago; carbamazepine up to 7 days ago and cyclin class antibiotics up to 30 days ago
研究者
相似试验
尚未招募
不适用
Clinical trial to evaluate the efficacy and safety of massage using a CMP-100 medical device in patients with shoulder-back myofascial pain syndromKCT0003971Wonkwang University, Gwangju Medical Center40
进行中（未招募）
不适用
Clinical trial to evaluate the efficacy and safety of MegaCarti® in Knee Cartilage DefectsDiseases of the musculoskeletal system and connective tissueKCT0004936&C BIO90
已完成
Unknown
Clinical trial to evaluate the efficacy and safety of nDM-14R intended for two-stage operation cases.Postoperative AdhesionJPRN-jRCT1092220091Kawasumi. laboratory .inc130
已完成
不适用
Clinical trial to evaluate the efficacy and safety of [11C]K-2 in healthy volunteershealthy volunteerJPRN-UMIN000020975Yokohama city university, school of medicine8
进行中（未招募）
不适用
Clinical trial with Transidose (=Lactulose) for oral intake regarding efficacy and safety in patients suffering from constipation.ConstipationMedDRA version: 18.1Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-002900-15-DESalsarulo Pharma